Headquarters: Waltham, Massachusetts, United States
52 week low:2.83
52 week high:7.75
Next ER:May 6, 2021 After Market Closes
Top Stories (CHMA)
Chiasma develops and commercializes oral therapies utilizing its proprietary Transient Permeability Enhancer (TPE®) technology to reduce the burden of chronic injections for people with rare diseases. Chiasma's proprietary TPE® technology is designed to convert select peptide based injectables into oral formulations. By leveraging this technology, patients may be alleviated of the burdens associated with chronic injectable therapies.
Talk about Chiasma Inc below in comments section below.
Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.